Prevalence of infectious diseases in patients with autoimmune blistering diseases

被引:4
|
作者
Ujiie, Inkin
Ujiie, Hideyuki
Yoshimoto, Norihiro
Iwata, Hiroaki
Shimizu, Hiroshi
机构
[1] Hokkaido Univ, Fac Med, Dept Dermatol, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
来源
JOURNAL OF DERMATOLOGY | 2020年 / 47卷 / 04期
关键词
screening; immunosuppressive treatment; autoimmune blistering disease; hepatitis B virus; Mycobacterium tuberculosis; B-VIRUS REACTIVATION; RECEIVING IMMUNOSUPPRESSIVE THERAPY; HEPATITIS-B; SYSTEMIC CHEMOTHERAPY; BLOOD-DONORS; TUBERCULOSIS; GUIDELINES; MANAGEMENT; JAPAN; MULTICENTER;
D O I
10.1111/1346-8138.15244
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A long-term immunosuppressive treatment can provoke latent infections. Autoimmune blistering diseases (AIBD) are mostly treated with systemic immunosuppressive agents. To prevent the reactivation or exacerbation of existing latent infections, patients must be screened for infectious diseases before immunosuppressive treatments are initiated. However, the prevalence of infectious diseases in AIBD remains to be elucidated. To evaluate the necessity of screening infectious diseases in AIBD, we retrospectively reviewed the clinical records of 215 patients at a single center with AIBD for hepatitis B virus (HBV), hepatitis C virus (HCV), Mycobacterium tuberculosis, Treponema pallidum, human T-cell leukemia virus type 1 (HTLV-1) and HIV infections. Approximately 40% of patients were infected with HBV. During systemic corticosteroid treatment, HBV DNA became positive in 3.4% of cases. Antibodies to HCV, interferon-gamma release assays for M. tuberculosis and the T. pallidum latex agglutination test were positive in 0.6%, 6.6% and 1.2% cases, respectively. Neither HTLV-1 nor HIV infections were detected. In conclusion, checks for HBV and M. tuberculosis infections should be made before immunosuppressive treatments are started, because of the high prevalence of these potentially life-threatening infections. Other infections should be tested for depending on the patient's risk factors.
引用
收藏
页码:378 / 384
页数:7
相关论文
共 50 条
  • [21] Complement and cutaneous autoimmune blistering diseases
    Elizabeth Lessey
    Ning Li
    Luis Diaz
    Zhi Liu
    Immunologic Research, 2008, 41 : 223 - 232
  • [22] Approach and Management of Autoimmune Blistering Diseases
    Zhao C.Y.
    Murrell D.F.
    Current Dermatology Reports, 2016, 5 (2) : 105 - 114
  • [23] News on the Pathogenesis of autoimmune blistering Diseases
    Borradori, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 33 - 34
  • [24] Diagnostic Techniques in Autoimmune Blistering Diseases
    Mee, John B.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2023, 80
  • [25] Diagnosis and classification of autoimmune blistering diseases
    Baum, Sharon
    Sakka, Nicole
    Artsi, Ofir
    Trau, Henri
    Barzilai, Aviv
    AUTOIMMUNITY REVIEWS, 2014, 13 (4-5) : 482 - 489
  • [26] Management of Autoimmune Blistering Diseases in Pregnancy
    McPherson, Tess
    Venning, Vanessa V.
    DERMATOLOGIC CLINICS, 2011, 29 (04) : 585 - +
  • [27] Autoimmune blistering diseases of the pemphigus group
    Calle Isaza, Juliana
    Avila Gomez, Isabel Cristina
    Abreu Velez, Ana Maria
    IATREIA, 2014, 27 (03) : 309 - 319
  • [28] Azathioprine in the Treatment of Autoimmune Blistering Diseases
    Meyer, Volker
    Beissert, Stefan
    DERMATOLOGIC CLINICS, 2011, 29 (04) : 545 - +
  • [29] Corticosteroid Use in Autoimmune Blistering Diseases
    Frew, John W.
    Murrell, Dedee F.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2012, 32 (02) : 283 - +
  • [30] Azathioprine in the Treatment of Autoimmune Blistering Diseases
    Meyer, Volker
    Beissert, Stefan
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2012, 32 (02) : 295 - +